Drug
Somavaratan clinical trials
Also written VRS-317.
- studies test it
- 10
- open now
- 1
- in phase 3
- 4
- first study started
- 2008
Keep track of what changes. Save the somavaratan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 6
- Phase 3
- 4
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 2
Versartis Inc. (8) · Baylor Breast Care Center (1) · Shanghai Zhongshan Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses somavaratan is read from its arms, and is right about nine times in ten.
Testing it · 10
- Effects of Growth Hormone Therapy on Metabolic Function in Fatty Liver Post-Pituitary Adenoma SurgeryRecruitingPhase 4Shanghai Zhongshan HospitalNCT06448195Written as Polyethylene Glycol Somatropin (rDNA origin) Injection
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)TerminatedPhase 2Versartis Inc.NCT02719990Written as somavaratan
- Long-Acting Growth Hormone in Children Compared to Daily rhGHCompletedPhase 3Versartis Inc.NCT02339090Written as Somavaratan
- Versartis International Trial in Adults With Long-Acting Growth HormoneCompletedPhase 2Versartis Inc.NCT02526420Written as somavaratan
- Versartis Trial in Children to Assess Long-Acting Growth HormoneCompletedPhase 1/2Versartis Inc.NCT01718041Written as Experimental: VRS-317
- Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)TerminatedPhase 2/3Versartis Inc.NCT02413138Written as Somavaratan (VRS-317)
- Lapatinib and Trastuzumab With or Without Endocrine TherapyCompletedPhase 2Baylor Breast Care CenterNCT00548184Written as Endocrine
- A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone DeficiencyTerminatedPhase 3Versartis Inc.NCT03145831Written as Somavaratan
- Versartis Long-Term Safety Study of SomavaratanTerminatedPhase 2/3Versartis Inc.NCT02068521Written as somavaratan
- VRS-317 in Adult Subjects With Growth Hormone DeficiencyCompletedPhase 1Versartis Inc.NCT01359488Written as VRS-317
Codes
What other systems call somavaratan · ClinicalTrials.gg INT014947
- UNII (FDA) 4Y05SI704SSOMAVARATANOne source FDA
- NCI Thesaurus C152398SomavaratanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4Y05SI704S | SOMAVARATAN | One source FDA |
| NCI Thesaurus | C152398 | Somavaratan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.